VincePatelMD(He/Him)

Clinical Trials

• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men Start of enrollment: 2018 May 03

  Completed

  Phase 4

• Investigational Study of Delayed Release Metformin Start of enrollment: 2021 May 18

  Suspended

  Phase 3

• A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Start of enrollment: 2021 Sep 30

  Terminated

  Phase 3

• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease Start of enrollment: 2022 Jan 11

  Completed

  Phase 2

• Strategic Targeting for Optimal Prevention of Cancer Start of enrollment: 2019 Mar 26

  Recruiting

• Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease Start of enrollment: 2020 Sep 14

  Completed

  Phase 2

• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight Start of enrollment: 2021 Mar 29

  Completed

  Phase 3

• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin Start of enrollment: 2022 Mar 08

  Active, not recruiting

  Phase 3

• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) Start of enrollment: 2017 Mar 23

  Terminated

  Phase 3

• S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Start of enrollment: 2019 Aug 13

  Recruiting

  Phase 3

• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2019 Aug 29

  Active, not recruiting

  Phase 3

• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20

  Active, not recruiting

  Phase 3

• A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma Start of enrollment: 2012 Feb 01

  Active, not recruiting

  Phase 3

• Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma Start of enrollment: 2015 Sep 01

  Active, not recruiting

  Phase 2

• Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma Start of enrollment: 2017 Jun 22

  Recruiting

  Phase 2

• ITIL-168 in Advanced Melanoma Start of enrollment: 2021 Oct 07

  Terminated

  Phase 2

• Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Start of enrollment: 2019 May 07

  Recruiting

  Phase 2

• Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma

  No longer available

• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease Start of enrollment: 2020 Jan 06

  Recruiting

  Phase 3

• Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Start of enrollment: 2023 Mar 16

  Recruiting

  Phase 2

• A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH Start of enrollment: 2023 Aug 08

  Active, not recruiting

  Phase 3

• MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes Start of enrollment: 2023 Oct 09

  Recruiting

  Phase 3

• Join now to see all